Europe Chinese Hamster Ovary (CHO) Cells Market, By Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
Europe Chinese Hamster Ovary (CHO) Cells Market Analysis and Insights
The Europe Chinese Hamster Ovary (CHO) cells market is a vital component of the biopharmaceutical industry, driven by the escalating demand for biologics and therapeutic proteins. CHO cells are a preferred choice for biopharmaceutical production due to their ability to efficiently express complex proteins with proper post-translational modifications.
Data Bridge Market Research analyzes that the Europe Chinese Hamster Ovary (CHO) cells market is expected to reach USD 190,312.23 thousand by 2030 from USD 104,656.51 thousand in 2022, growing at a substantial CAGR of 8.2% in the forecast period of 2023 to 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, ASP in USD, and Volume in Thousand
|
|
Segments Covered
|
Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
|
Countries Covered
|
Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, and Rest of Europe
|
|
Market Players Covered
|
Abeomics, AcceGen, Applied Biological Materials Inc. (abm), ATCC, BPS Bioscience, Inc., CLS Cell Lines Service GmbH, Curia Global, Inc., Cytiva, GenTarget Inc., GTP Bioways, Horizon Discovery Ltd., Lonza, Merck KGaA, Promega Corporation, RayBiotech Life, Inc., Sartorius AG, Thermo Fisher Scientific Inc. and among others
|
Market Definition
Chinese Hamster Ovary (CHO) cells are a type of mammalian cell line commonly used in biotechnology and biomedical research, particularly in the field of cell culture and bioprocessing. These cells have become essential tools in biotechnology and biomedical research. CHO cells are known for their adherence to culture surfaces, robust growth characteristics, and ability to express recombinant proteins. Their popularity stems from their similarity to human cells, making them suitable for studying biological processes and producing biopharmaceuticals.
Europe Chinese Hamster Ovary (CHO) Cells Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Use of CHO Cells in the Genetic Study
CHO cells have gained prominence in genetic research due to their adaptability and versatility in genetic manipulation and expression systems. Researchers and biotechnologists across Europe are increasingly relying on CHO cells to investigate various aspects of genetics, including gene expression, genome editing, and functional genomics.
CHO cells provide a stable and well-characterized platform for genetic studies, making them an essential resource for understanding gene function, protein expression, and the development of new therapeutic agents. This heightened interest in genetic research using CHO cells not only fuels the demand for CHO cells but also drives innovations in biotechnology and genetic engineering techniques. Consequently, the market is experiencing growth as it caters to the expanding needs of the scientific community engaged in genetic research and biotechnology, further solidifying its position in the life sciences sector.
- Growing Demand for Biopharmaceuticals
CHO cells play a vital role in the production of biopharmaceuticals, such as monoclonal antibodies, vaccines, and therapeutic proteins. With an aging population and increasing healthcare needs in Europe, there is a rising demand for these advanced medicines. CHO cells offer a reliable and efficient platform for large-scale biopharmaceutical production, making them indispensable for the biomanufacturing process. The market is experiencing steady growth, reinforcing its crucial role in the biopharmaceutical industry as pharmaceutical companies and biotechnology firms seek to meet the demand for innovative therapies and vaccines.
Restraint
- High Cost of CHO Cell-based Production
The high cost of CHO cell-based production serves as a significant restraint for market growth as this cost factor can limit the widespread adoption of CHO cell technology for biopharmaceutical production, impacting the affordability and accessibility of biopharmaceuticals in the European market.
Opportunity
-
Continuous Development of Cell Culture Technologies
The ongoing advancements in cell culture technologies create a promising opportunity for the market growth by facilitating improved productivity, scalability, and cost-effectiveness in the production of biopharmaceuticals.
Challenge
- Time-consuming and Inconsistency in CHO Cell Line Development Process
Developing stable and high-yielding CHO cell lines for biopharmaceutical production can be a lengthy and resource-intensive endeavor. Variability in cell line performance and characteristics can lead to unpredictability in production, which affects the overall efficiency and cost-effectiveness of biopharmaceutical manufacturing.
The need to optimize and characterize cell lines, select appropriate clones, and achieve consistent productivity levels can extend development timelines and increase operational costs. This challenge not only affects time-to-market for new biopharmaceuticals but also adds complexity to regulatory compliance and quality assurance efforts. Consequently, addressing the time-consuming and inconsistent nature of the CHO cell line development process is essential to enhance the competitiveness of the market in the biopharmaceutical industry.
Recent Developments
- In July 2023, Lonza launched TheraPRO CHO Media System, a new cell culture medium that simplifies processes and optimizes productivity and protein quality when using GS-CHO cell lines. The startup supports pharmaceutical and biotech companies producing therapeutic proteins to further improve product quality. The TheraPRO CHO Media System provides efficient performance, achieving high concentrations of viable cells and protein titers above 5 g/L over a 15-day culture period. This represents more than double the protein titer that can be produced with commercially available solutions. This launch helped the company to expand its product portfolio in the market.
- In July 2023, Merck KGaA announced that it is expanding its facility in Lenexa, Kansas, U.S., adding 9,100 square meters of laboratory space and production capacity for the production of cell culture media. This expansion made Lenexa the company's largest dry powder cell culture facility and a center of excellence in North America. The investment in the region reflected the company's strategy to expand and diversify its supply chain to meet current and future demand for cell culture platforms.
- In June 2023, Curia Global, Inc., a leading contract research, development, and manufacturing company, announced that it has signed a license agreement with North American life sciences company Millipore Sigma, Merck KGaA in Darmstadt, Germany, which will allow Curia and its customers to use CHOZN. GS-/- cell line for the production of proteins and antibodies for therapeutic purposes. Following the agreement, the CHOZN GS-/- cell line will be integrated into Curia's cell line development workflow and immediately available to Curia's customers.
- In November 2022, ATCC, the world's leading regulatory and standards organization for biological materials, announced a new line of CAR-T Target luciferase reporter cell lines to support immuno-oncology (IO) discovery and the development of new immunotherapies. These models have a high endogenous expression of relevant chimeric antigen receptor (CAR) T target antigens such as HER2, CD19, and CD20. These new IO tools consist of both hematologic cancers and solid tumor cell lines expressing a luciferase reporter. This helped the company to expand its product portfolio.
- In October 2022, Thermo Fisher Scientific Inc. collaborated with ProBioGen to develop an even better platform, the Gibco Freedom ExpiCHO-S Cell Line Development Kit. This kit allows users to generate cell lines suitable for clinical development without their own original cells, vectors, or previous experience in the field. ProBioGen significantly contributed to the performance of the Freedom ExpiCHO-S kit by leveraging its strong expertise in cell line and process development. The new series utilizes Thermo Fisher's ExpiCHO-S cell line, expanding the company's product portfolio for the CHO cell line development series.
Europe Chinese Hamster Ovary (CHO) Cells Market Scope
The Europe Chinese Hamster Ovary (CHO) cells market is segmented into five notable segments based on type, system, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Services
- Product
On the basis of type, the market is segmented into services and product.
System
- Metabolic Selection System
- Antibiotic Selection System
- Others
On the basis of system, the market is segmented into metabolic selection system, antibiotic selection system, and others.
Application
- Biologics
- Medical Research
On the basis of application, the market is segmented into biologics and medical research.
End User
- Biopharmaceutical Companies
- Biotechnology Companies
- Clinical Development and Manufacturing Organizations
- Clinical Research Organizations
- Academic Institutes and Research Organizations
- Others
On the basis of end user, the market is segmented into biopharmaceutical companies, biotechnology companies, clinical development and manufacturing organizations, clinical research organizations, academic institutes and research organizations, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tenders, retail sales, and others.
Europe Chinese Hamster Ovary (CHO) Cells Market Regional Analysis/Insights
The Europe Chinese Hamster Ovary (CHO) cells market is segmented into five notable segments based on type, system, application, end user, and distribution channel.
The countries covered in this market report are Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, and Rest of Europe.
Germany is expected to dominate the Europe Chinese Hamster Ovary (CHO) cells market due to the country's strong biopharmaceutical industry with a focus on innovative therapies and vaccines, increasing the demand for CHO cells in bioproduction.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Chinese Hamster Ovary (CHO) Cells Market Share Analysis
Europe Chinese Hamster Ovary (CHO) cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the Europe Chinese Hamster Ovary (CHO) cells market are Abeomics, AcceGen, Applied Biological Materials Inc. (abm), ATCC, BPS Bioscience, Inc., CLS Cell Lines Service GmbH, Curia Global, Inc., Cytiva, GenTarget Inc., GTP Bioways, Horizon Discovery Ltd., Lonza, Merck KGaA, Promega Corporation, RayBiotech Life, Inc., Sartorius AG, Thermo Fisher Scientific Inc. and among others.
SKU-